AtaiBeckley Inc. (NASDAQ: ATAI) announced it has dosed the last patient in its Elumina Phase 2b clinical trial evaluating VLS-01 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE